Evidence map›Paper›PMID 39310693›Full record

ArticleActa clinica Croatica2023

PHARMACOVIGILANCE IN SERBIA: A TEN-YEAR PHARMACOEPIDEMIOLOGIC ANALYSIS.

Dejan Živanović, Vesna Mijatović Jovin, Jovan Javorac, Isidora Samojlik, Aleksandar Rašković, Marija Jevtić, Svetlana Stojkov, Nataša Jovanović Lješković, Nataša Perković Vukčević

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta clinica Croatica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dejan ŽivanovićDepartment of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Vesna Mijatović JovinDepartment of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Jovan JavoracInstitute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia.
Isidora SamojlikDepartment of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Aleksandar RaškovićDepartment of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Marija JevtićInsitute for Public Health of Vojvodina, Novi Sad, Serbia.
Svetlana StojkovFaculty of Pharmacy, University of Business Academy, Novi Sad, Serbia.
Nataša Jovanović LješkovićFaculty of Pharmacy, University of Business Academy, Novi Sad, Serbia.
Nataša Perković VukčevićMilitary Medical Academy, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacovigilance as a science and group of activities related to detection, collection, analysis, understanding and prevention of adverse drug reactions (ADRs) is an essential activity in the regulatory system of drugs of any country. Defining increased patient safety as the main purpose of ADR reporting, a well-designed national pharmacovigilance system achieves its ultimate goal, i.e., protection of public health. In organizational and technical terms, the Republic of Serbia has a well-developed system of pharmacovigilance, created on the basis of a proven reliable system of the former SFR Yugoslavia, and carried out by the National Agency for Medicines and Medical Devices of Serbia (ALIMS), which conducts all organized activities aimed at strengthening the national system of ADR monitoring and reporting. Unlike the neighboring Croatia and Montenegro with similar pharmacovigilance systems, Serbia has only recently approached the WHO standard of 200 reports

Indexed as

Adverse Drug Reaction Reporting SystemsPharmacoepidemiologyPharmacovigilanceDrug-Related Side Effects and Adverse ReactionsHumansSerbiaAdverse drug reaction monitoring and reportingAdverse drug reactionsAdverse events following immunizationSuspected drug

Identifiers

PMID39310693
PMCPMC11413999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.